A moderate-fat diet containing pistachios improves emerging markers of cardiometabolic syndrome in healthy adults with elevated LDL levels

British Journal of Nutrition

Volumn 112, Issue 5, 2014, Pages 744-752

  Holligan, Simone D ^a   West, Sheila G ^a   Gebauer, Sarah K ^a,b   Kay, Colin D ^a,c   Kris Etherton, Penny M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

C reactive protein; Cardiometabolic disease; HDL subclasses; Insulin resistance; Pistachios; Plant sterols; Small and dense LDL

Indexed keywords

ABC TRANSPORTER A1; C REACTIVE PROTEIN; CAMPESTEROL; DESMOSTEROL; HIGH DENSITY LIPOPROTEIN; LATHOSTEROL; LOW DENSITY LIPOPROTEIN; SITOSTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOMETABOLIC SYNDROME; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSSOVER PROCEDURE; DIET THERAPY; FAT INTAKE; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; NORMAL HUMAN; PISTACHIO; RANDOMIZED CONTROLLED TRIAL;

PISTACIA VERA;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; CROSS-OVER STUDIES; DIETARY FATS; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTS; PHYTOSTEROLS; PHYTOTHERAPY; PISTACIA; SITOSTEROLS; TRIGLYCERIDES;

EID: 84907598986     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114514001561     Document Type: Article

References (49)

1. Alberti KGMM, Eckel RH, Grundy SM, et al. (2009) Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645.
2. O'Neil CE, Keast DR, Nicklas TA, et al. (2011) Nut consumption is associated with decreased health risk factors for cardiovascular disease and metabolic syndrome in U.S. adults: NHANES 1999-2004. J Am Coll Nutr 30, 502-510.
3. Sabaté J (1999) Nut consumption, vegetarian diets, ischemic heart disease risk, and all-cause mortality: Evidence from epidemiologic studies. Am J Clin Nutr 70, Suppl. 3, 500S-503S.
4. Jaceldo-Siegl K, Haddad E, Oda K, et al. (2014) Tree nuts are inversely associated with metabolic syndrome and obesity: The Adventist Health Study-2. PLOS ONE 9, e85133.
5. Bao Y, Han J, Hu FB, et al. (2013) Association of nut consumption with total and cause-specific mortality. N Engl J Med 369, 2001-2011.
6. Phillips KM, Ruggio DM & Ashraf-Khorassani M (2005) Phytosterol composition of nuts and seeds commonly consumed in the United States. J Agric Food Chem 53, 9436-9445.
7. DGAC (2010) Report of the Dietary Guidelines Advisory Committee on the Dietary Guidelines for Americans. Washington, DC: US Department of Agriculture, US Department of Health and Human Services.
8. Gylling H, Plat J & Turley S (2014) Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 232, 346-360.
9. Sabaté J, Oda K & Ros E (2010) Nut consumption and blood lipid levels: A pooled analysis of 25 intervention trials. Arch Intern Med 170, 821-827.
10. Appel LJ, Sacks FM, Carey VJ, et al. (2005) Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the OmniHeart randomized trial. JAMA 294, 2455-2464.
11. Zavaroni I, Bonora E, Pagliara M, et al. (1989) Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 320, 702-706.
12. Karhapää P, Malkki M & Laakso M (1994) Isolated low HDL cholesterol: An insulin-resistant state. Diabetes 43, 411-417.
13. McLaughlin T, Abbasi F, Cheal K, et al. (2003) Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139, 802-809.
14. Bittner V, Johnson BD, Zineh I, et al. (2009) The triglyceride/high- density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A report from the Women's Ischemia Syndrome Evaluation (WISE). Am Heart J 157, 548-555.
15. Onat A, Can G, Kaya H, et al. (2010) "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol 4, 89-98.
16. Garvey WT, Kwon S, Zheng D, et al. (2003) Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52, 453-462.
17. Irving BA, Nair KS & Srinivasan M (2011) Effects of insulin sensitivity, body composition, and fitness on lipoprotein particle sizes and concentrations determined by nuclear magnetic resonance. J Clin Endocrinol Metab 96, E713-E718.
18. Krauss RM (2010) Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 21, 305-311.
19. Reaven GM, Chen YD, Jeppesen J, et al. (1993) Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92, 141-146.
20. Castelli WP, Garrison RJ, Wilson PW, et al. (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256, 2835-2838.
21. Sharrett AR, Ballantyne CM, Coady SA, et al. (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104, 1108-1113.
22. Gardner CD, Fortmann SP & Krauss RM (1996) Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276, 875-881.
23. Galeano NF, Al-Haideri M, Keyserman F, et al. (1998) Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: A potential mechanism for increased atherogenicity. J Lipid Res 39, 1263-1273.
24. Asztalos BF, Collins D, Cupples LA, et al. (2005) Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 25, 2185-2191.
25. Asztalos BF, Cupples LA, Demissie S, et al. (2004) Highdensity lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24, 2181-2187.
26. Asztalos BF, de la Llera-Moya M, Dallal GE, et al. (2005) Differential effects of HDL subpopulations on cellular ABCA1-and SR-BI-mediated cholesterol efflux. J Lipid Res 46, 2246-2253.
27. Fielding CJ & Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36, 211-228.
28. Rothblat GH & Phillips MC (2010) High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 21, 229-238.
29. Gebauer SK, West SG, Kay CD, et al. (2008) Effects of pistachios on cardiovascular disease risk factors and potential mechanisms of action: A dose-response study. Am J Clin Nutr 88, 651-659.
30. Jenkins DJ, Kendall CW, Marchie A, et al. (2002) Dose response of almonds on coronary heart disease risk factors: Blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: A randomized, controlled, crossover trial. Circulation 106, 1327-1332.
31. Sabaté J, Haddad E, Tanzman JS, et al. (2003) Serum lipid response to the graduated enrichment of a Step I diet with almonds: A randomized feeding trial. Am J Clin Nutr 77, 1379-1384.
32. Ai M, Otokozawa S, Asztalos BF, et al. (2010) Small dense LDL cholesterol and coronary heart disease: Results from the Framingham Offspring Study. Clin Chem 56, 967-976.
33. Lamon-Fava S, Marcovina SM, Albers JJ, et al. (2011) Lipoprotein( a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 52, 1181-1187.
34. Pearson TA, Mensah GA, Alexander RW, et al. (2003) AHA/CDC Scientific Statement. Markers of Inflammation and Cardiovascular Disease. Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511.
35. Matthews DR, Hosker JP, Rudenski AS, et al. (1985) Homeostasis model assessment: Insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419.
36. Mweva S, Paul JL, Cambillau M, et al. (2006) Comparison of different cellular models measuring in vitro the whole human serum cholesterol efflux capacity. Eur J Clin Invest 36, 552-559.
37. de la Llera Moya M, Drazul-Schrader D, Asztalos BF, et al. (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30, 796-801.
38. Matthan NR, Giovanni A, Schaefer EJ, et al. (2003) Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL. J Lipid Res 44, 800-806.
39. van Himbergen TM, Matthan NR, Resteghini NA, et al. (2009) Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res 50, 730-739.
40. Hirschfield GM & Pepys MB (2003) C-reactive protein and cardiovascular disease: New insights from an old molecule. QJM 96, 793-807.
41. Rifai N (2005) High-sensitivity C-reactive protein: A useful marker for cardiovascular disease risk prediction and the metabolic syndrome. Clin Chem 51, 504-505.
42. Austin MA, King MC, Vranizan KM, et al. (1990) Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82, 495-506.
43. Salazar MR, Carbajal HA, Espeche WG, et al. (2013) Comparison of the abilities of the plasma triglyceride/high-density lipoprotein cholesterol ratio and the metabolic syndrome to identify insulin resistance. Diab Vasc Dis Res 10, 346-352.
44. Taskinen MR (2003) LDL-cholesterol, HDL-cholesterol or triglycerides-which is the culprit Diabetes Res Clin Pract 61, Suppl. 1, S19-S26.
45. Luc G, Bard JM, Arveiler D, et al. (2002) Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis 163, 377-384.
46. Normen L, Dutta P, Lia A, et al. (2000) Soy sterol esters and b-sitostanol ester as inhibitors of cholesterol absorption in human small bowel. Am J Clin Nutr 71, 908-913.
47. Escurriol V, Cofan M, Serra M, et al. (2009) Serum sterol responses to increasing plant sterol intake from natural foods in the Mediterranean diet. Eur J Nutr 48, 373-382.
48. Nguyen TT (1999) The cholesterol-lowering action of plant stanol esters. J Nutr 129, 2109-2112.
49. Taverne F, Richard C, Couture P, et al. (2013) Abdominal obesity, insulin resistance, metabolic syndrome and cholesterol homeostasis. PharmaNutrition 1, 130-136.